These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 2189619)

  • 21. ACE inhibitors versus diuretics: when to choose which drug?
    Sharpe N
    Cardiovasc Drugs Ther; 1993 Dec; 7(6):877-9. PubMed ID: 8011562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin antagonism in patients with heart failure: ACE inhibitors, angiotensin receptor antagonists or both?
    Cruden NL; Newby DE
    Am J Cardiovasc Drugs; 2004; 4(6):345-53. PubMed ID: 15554719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lessons from recent randomized controlled trials for the management of congestive heart failure.
    Riegger GA
    Am J Cardiol; 1993 Jun; 71(17):38E-40E. PubMed ID: 8328366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?
    MacFadyen RJ; Lee AF; Morton JJ; Pringle SD; Struthers AD
    Heart; 1999 Jul; 82(1):57-61. PubMed ID: 10377310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors.
    Sigurdsson A
    Blood Press Suppl; 1995; 1():1-45. PubMed ID: 7599749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Indications for ACE inhibitors in chronic heart failure].
    Erdmann E
    Z Kardiol; 1994; 83 Suppl 4():75-9. PubMed ID: 7856285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction.
    Sander GE; McKinnie JJ; Greenberg SS; Giles TD
    Prog Cardiovasc Dis; 1999; 41(4):265-300. PubMed ID: 10362349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Progress in management for heart failure: diuretics].
    Aoyagi T; Hirata Y
    Nihon Rinsho; 1993 May; 51(5):1281-6. PubMed ID: 8331795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Side effects of vasodilator therapy in heart failure: risk of hypotension with ACE inhibitors].
    Kromer EP; Elsner D; Riegger GA
    Z Kardiol; 1991; 80 Suppl 2():11-5. PubMed ID: 2024538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin-converting enzyme inhibitors in the clinical setting of chronic congestive heart failure.
    Reyes AJ
    Am J Cardiol; 1995 Jun; 75(18):50F-55F. PubMed ID: 7778535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fundamental role of angiotensin-converting enzyme inhibitors in the management of congestive heart failure.
    Opie LH
    Am J Cardiol; 1995 Jun; 75(18):3F-6F. PubMed ID: 7778532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Acetylsalicylic acid antagonism vs ACE inhibitor in congestive heart failure as shown by a diminished respiratory and exercise capacity].
    Guazzi M; Lauri G; Melzi G; Cattadori G; Agostoni P
    Cardiologia; 1996 Jun; 41(6):527-33. PubMed ID: 8766415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin-converting enzyme inhibitors in congestive heart failure.
    Deedwania PC
    Arch Intern Med; 1990 Sep; 150(9):1798-805. PubMed ID: 2132302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect of monotherapy (data from the trial SADKO-CHF)].
    Skvortsov AA; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Mareev VIu; Belenkov IuN
    Ter Arkh; 2005; 77(8):34-43. PubMed ID: 16206603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New competition in the realm of renin-angiotensin axis inhibition; the angiotensin II receptor antagonists in congestive heart failure.
    Martineau P; Goulet J
    Ann Pharmacother; 2001 Jan; 35(1):71-84. PubMed ID: 11197588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Drug treatment for chronic heart failure with reduced ejection fraction].
    Rickenbacher P
    Ther Umsch; 2011 Feb; 68(2):71-9. PubMed ID: 21271537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal functional alterations induced by angiotensin-converting enzyme inhibitors in heart failure.
    Munger MA
    Ann Pharmacother; 1993 Feb; 27(2):205-10. PubMed ID: 8439700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Refocus on diuretics in the treatment of heart failure.
    Taylor SH
    Eur Heart J; 1995 Jul; 16 Suppl F():7-15. PubMed ID: 8521885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
    Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ
    Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin converting enzyme inhibitors and moderate hypertension.
    McAreavey D; Robertson JI
    Drugs; 1990 Sep; 40(3):326-45. PubMed ID: 2226219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.